Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2022 Filed May 18, 2022 20:34 UTC |
DArecca JamesEVP, Chief Financial Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 11,163 | $0.00 Strike: $57.60 | $0.00 |
DisclosureSEC source: 0001127602-22-014966 · form4.xml · derivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,163 Underlying: Common Stock · 11,163 shares Expires 2029-05-16 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:34 UTC |
DArecca JamesEVP, Chief Financial Officer
|
GrantCommon Stock | 4,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-014966 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,676 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:26 UTC |
Simon, ChristopherDirector · President & CEO
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 60,891 | $0.00 Strike: $57.60 | $0.00 |
DisclosureSEC source: 0001127602-22-014951 · form4.xml · derivative · entry 3 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,891 Underlying: Common Stock · 60,891 shares Expires 2029-05-16 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:26 UTC |
Simon, ChristopherDirector · President & CEO
|
GrantCommon Stock | 26,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-014951 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,368 F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:26 UTC |
Simon, ChristopherDirector · President & CEO
|
SaleCommon Stock | 832 | $56.10 | $46,675.20 |
DisclosureSEC source: 0001127602-22-014951 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,327 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022. Read SEC document |
| May 02, 2022 Filed May 4, 2022 20:41 UTC |
DArecca JamesEVP, Chief Financial Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 13,828 | $0.00 Strike: $50.83 | $0.00 |
DisclosureSEC source: 0001127602-22-013206 · form4.xml · derivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,828 Underlying: Common Stock · 13,828 shares Expires 2029-05-02 F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 02, 2022 Filed May 4, 2022 20:41 UTC |
DArecca JamesEVP, Chief Financial Officer
|
GrantCommon Stock | 5,902 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013206 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,902 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 20:19 UTC |
Lingamneni AnilaEVP, Chief Technology Officer
|
SaleCommon Stock | 189 | $56.55 | $10,687.95 |
DisclosureSEC source: 0001127602-22-012143 · form4.xml · nonDerivative · entry 1 Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,013 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 20:58 UTC |
Strong Stewart WPresident, Global Hospital
|
SaleCommon Stock | 75 | $71.93 | $5,394.75 |
DisclosureSEC source: 0001127602-21-027704 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,717 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 20:49 UTC |
Basil Michelle LEVP and General Counsel
|
SaleCommon Stock | 120 | $71.93 | $8,631.60 |
DisclosureSEC source: 0001127602-21-027702 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,290 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| September 17, 2021 Filed Sep 22, 2021 01:20 UTC |
Miller Laurie A.SVP, Human Resources
|
GrantCommon Stock | 2,848 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036959 · doc4.xml · nonDerivative · entry 1 Miller Laurie A. · CIK 0001881751 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,081 F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Equity Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Equity Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This includes unvested RSUs previously reported. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:56 UTC |
Llorens JosepEVP, Global Manufacturing
|
SaleCommon Stock | 100 | $64.61 | $6,461.00 |
DisclosureSEC source: 0000899243-21-035451 · doc4.xml · nonDerivative · entry 1 Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,520 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:15 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 11,435 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0000899243-21-034143 · doc4.xml · derivative · entry 5 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,435 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:15 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 11,232 | $0.00 Strike: $34.21 | $0.00 |
DisclosureSEC source: 0000899243-21-034143 · doc4.xml · derivative · entry 4 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,232 shares Expires 2023-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:15 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
SaleCommon Stock | 22,667 | $60.51 | $1,371,580.17 |
DisclosureSEC source: 0000899243-21-034143 · doc4.xml · nonDerivative · entry 3 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,291 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · price: Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $60.06 to $60.88, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:15 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 11,435 | $41.64 | $476,153.40 |
DisclosureSEC source: 0000899243-21-034143 · doc4.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:15 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 11,232 | $34.21 | $384,246.72 |
DisclosureSEC source: 0000899243-21-034143 · doc4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 23:30 UTC |
Pomeroy ClaireDirector
|
GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023397 · form4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,016 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 23:25 UTC |
KROLL MARK WDirector
|
GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023396 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,517 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 23:22 UTC |
Dockendorff Charles JDirector
|
GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023395 · form4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,400 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: Includes 8,568 shares previously held by a grantor retained annuity trust, of which Mr. Dockendorff is the sole trustee, pursuant to an exempt transfer by such trust. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 23:18 UTC |
COYLE MICHAEL JDirector
|
GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023393 · form4.xml · nonDerivative · entry 1 COYLE MICHAEL J · CIK 0001233311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,538 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 23:14 UTC |
BURZIK CATHERINE MDirector
|
GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023391 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,815 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 23:10 UTC |
ABERNATHY ROBERT EDirector
|
GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023389 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,125 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 22:54 UTC |
Johnson Lloyd EmersonDirector
|
GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023386 · form4.xml · nonDerivative · entry 1 Johnson Lloyd Emerson · CIK 0001708823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,077 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 22:59 UTC |
Zane Ellen MDirector
|
GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023387 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,517 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:21 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
SaleCommon Stock | 4,293 | $66.60 | $285,913.80 |
DisclosureSEC source: 0001127602-21-021568 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,291 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:39 UTC |
Goldstein DanVP, Corporate Controller
|
SaleCommon Stock | 39 | $59.87 | $2,334.93 |
DisclosureSEC source: 0001127602-21-020056 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,054 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:35 UTC |
Basil Michelle LEVP and General Counsel
|
SaleCommon Stock | 195 | $59.87 | $11,674.65 |
DisclosureSEC source: 0001127602-21-020055 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,410 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:31 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
SaleCommon Stock | 190 | $59.87 | $11,375.30 |
DisclosureSEC source: 0001127602-21-020050 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,584 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:29 UTC |
Simon, ChristopherDirector · President & CEO
|
SaleCommon Stock | 1,200 | $59.87 | $71,844.00 |
DisclosureSEC source: 0001127602-21-020048 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,806 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:35 UTC |
Goldstein DanVP, Corporate Controller
|
SaleCommon Stock | 81 | $55.09 | $4,462.29 |
DisclosureSEC source: 0001127602-21-019529 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,093 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:33 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
SaleCommon Stock | 195 | $55.09 | $10,742.55 |
DisclosureSEC source: 0001127602-21-019526 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,216 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:31 UTC |
Basil Michelle LEVP and General Counsel
|
SaleCommon Stock | 442 | $55.09 | $24,349.78 |
DisclosureSEC source: 0001127602-21-019523 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,605 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:29 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
SaleCommon Stock | 411 | $55.09 | $22,641.99 |
DisclosureSEC source: 0001127602-21-019522 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,774 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:27 UTC |
Simon, ChristopherDirector · President & CEO
|
SaleCommon Stock | 2,715 | $55.09 | $149,569.35 |
DisclosureSEC source: 0001127602-21-019521 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,006 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:42 UTC |
Goldstein DanVP, Corporate Controller
|
GrantCommon Stock | 1,753 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-018998 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,174 F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant. F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:09 UTC |
KROLL MARK WDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,353 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001127602-21-018310 · form4.xml · derivative · entry 3 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,353 shares Expires 2021-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vests 100% on the first anniversary of the date of grant. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:09 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 11,813 | $55.10 | $650,896.30 |
DisclosureSEC source: 0001127602-21-018310 · form4.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,440 F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:09 UTC |
KROLL MARK WDirector
|
Exercise / conversionCommon Stock | 10,353 | $35.50 | $367,557.38 |
DisclosureSEC source: 0001127602-21-018310 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 19, 2021 Filed May 20, 2021 22:08 UTC |
Goldstein DanVP, Corporate Controller
|
SaleCommon Stock | 42 | $55.19 | $2,317.98 |
DisclosureSEC source: 0001127602-21-017683 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,421 F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 19, 2021 Filed May 20, 2021 22:07 UTC |
Lingamneni AnilaEVP, Chief Technology Officer
|
SaleCommon Stock | 92 | $55.19 | $5,077.48 |
DisclosureSEC source: 0001127602-21-017682 · form4.xml · nonDerivative · entry 3 Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,202 F5 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021. Read SEC document |
| May 19, 2021 Filed May 20, 2021 22:05 UTC |
Llorens JosepSVP, Global Manufacturing
|
SaleCommon Stock | 125 | $55.19 | $6,898.75 |
DisclosureSEC source: 0001127602-21-017681 · form4.xml · nonDerivative · entry 3 Llorens Josep · CIK 0001750812 · SVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,620 F5 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 19, 2021 Filed May 20, 2021 22:02 UTC |
Basil Michelle LEVP and General Counsel
|
SaleCommon Stock | 220 | $55.19 | $12,141.80 |
DisclosureSEC source: 0001127602-21-017680 · form4.xml · nonDerivative · entry 3 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,047 F5 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 19, 2021 Filed May 20, 2021 21:58 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
SaleCommon Stock | 238 | $55.19 | $13,135.22 |
DisclosureSEC source: 0001127602-21-017677 · form4.xml · nonDerivative · entry 3 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,185 F5 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 19, 2021 Filed May 20, 2021 21:55 UTC |
Simon, ChristopherDirector · President & CEO
|
SaleCommon Stock | 1,024 | $55.19 | $56,514.56 |
DisclosureSEC source: 0001127602-21-017675 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,721 F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 19, 2021 Filed May 21, 2021 10:26 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
SaleCommon Stock | 112 | $55.19 | $6,181.28 |
DisclosureSEC source: 0001127602-21-017698 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,411 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2021 Filed May 20, 2021 22:08 UTC |
Goldstein DanVP, Corporate Controller
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 2,690 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001127602-21-017683 · form4.xml · derivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,690 Underlying: Common Stock · 2,690 shares Expires 2028-05-18 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 18, 2021 Filed May 20, 2021 22:08 UTC |
Goldstein DanVP, Corporate Controller
|
GrantCommon Stock | 994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-017683 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,463 F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2021 Filed May 20, 2021 22:07 UTC |
Lingamneni AnilaEVP, Chief Technology Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,564 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001127602-21-017682 · form4.xml · derivative · entry 4 Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,564 Underlying: Common Stock · 9,564 shares Expires 2028-05-18 F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 18, 2021 Filed May 20, 2021 22:07 UTC |
Lingamneni AnilaEVP, Chief Technology Officer
|
GrantCommon Stock | 7,070 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-017682 · form4.xml · nonDerivative · entry 2 Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,294 F4 · kind: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant. F4 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.